Clinical trial · Interventional
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults
NCT00114920CI-TRIAL-00000610completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks. A second purpose is to evaluate the safety of the drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Warts | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Resiquimod | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Clearance of treated common wart(s)
Secondary outcomes (2)
- measure
- Partial clearance of treated common wart(s)
- measure
- Wart recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of common warts * Two forms of birth control Exclusion Criteria: * Pregnant or breast feeding * Other types of wart(s), ie. plantar * Currently participating in another clinical study * Chronic viral hepatitis B or C
References
Publications (0)
Data not yet available
No reference posted for this study.